Drug Profile
Research programme: cancer therapeutics - Ayala Pharmaceuticals
Alternative Names: ADXS-508; ADXS-HOTLatest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Advaxis
- Developer Ayala Pharmaceuticals
- Class Cancer vaccines; Recombinant fusion proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Colorectal cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)
- 19 Jan 2023 Advaxis has merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals
- 28 Oct 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Infusion)